Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 39

Results For "United-States"

964 News Found

Zydus receives USFDA’s approvals for Pimavanserin Capsules, 34 mg and Pimavanserin Tablets,10 mg
Drug Approval | January 18, 2024

Zydus receives USFDA’s approvals for Pimavanserin Capsules, 34 mg and Pimavanserin Tablets,10 mg

Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis


NovaBay and Sonoma to market Avenova-branded products in EU through Sonoma’s distributor network
Supply Chain | January 16, 2024

NovaBay and Sonoma to market Avenova-branded products in EU through Sonoma’s distributor network

Sonoma will manufacture Ocudox by Avenova with packaging similar to NovaBay’s Avenova products


Lupin launches Varenicline Tablets in US
News | January 11, 2024

Lupin launches Varenicline Tablets in US

Varenicline Tablets (RLD Chantix) had estimated annual sales of US $412 million in the US


Unichem receives ANDA approval for Doxazosin Tablets
Drug Approval | January 11, 2024

Unichem receives ANDA approval for Doxazosin Tablets

Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure


Lupin Launches Bromfenac Ophthalmic Solution, 0.07% in US
News | January 10, 2024

Lupin Launches Bromfenac Ophthalmic Solution, 0.07% in US

Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa Ophthalmic Solution, 0.07%, of Bausch & Lomb


Merck to acquire Harpoon Therapeutics for US$ 680 million
News | January 10, 2024

Merck to acquire Harpoon Therapeutics for US$ 680 million

Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors


Cipla announces JV with Kemwell Biopharma and Manipal Education & Medical Group
News | January 09, 2024

Cipla announces JV with Kemwell Biopharma and Manipal Education & Medical Group

The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions


Cipla Technologies, Pulmatrix agree for development and commercialization of Pulmazole
News | January 08, 2024

Cipla Technologies, Pulmatrix agree for development and commercialization of Pulmazole

Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America